Makati

Philippines

Phone Number

0962 950 7814
(02) 8637-2360

Send Your Mail

slcelitemedicalcare@gmail.com

Inquire Now

Yttrium-90 (Y-90) Radioembolization

  • Home
  • Yttrium-90 (Y-90) Radioembolization

Yttrium-90 (Y-90) Radioembolization: Targeted Liver Cancer Therapy

Yttrium-90 (Y-90) is a radioactive isotope produced by irradiating stable yttrium-89 (Y-89), which has a half-life of 2.66 days. Y-90 decays to stable zirconium-90 (Zr-90) while emitting beta radiation. In medical applications, radioactive microspheres containing Yttrium-90 are used in a procedure known as radioembolization or selective internal radiation therapy (SIRT).

These microspheres, loaded with Y-90, are injected directly into the liver artery through precise catheter placement. This targeted delivery ensures that the microspheres travel directly to the tumor site, where they become lodged in the smaller blood vessels feeding the tumor. Once implanted, the Y-90 microspheres continuously emit beta particles locally, delivering concentrated radiation to the tumor cells and causing cellular damage and tumor cell death. The beta radiation is effective at destroying tumor tissue while minimizing exposure to surrounding healthy tissue, making it a powerful treatment for liver tumors, including primary liver cancer (hepatocellular carcinoma) and metastatic liver cancer.

How It Works

Production and Decay:

  • Yttrium-90 is produced by irradiating stable yttrium-89 (Y-89). Y-90 has a half-life of 2.66 days, decaying into stable zirconium-90 (Zr-90) through the emission of beta radiation.

 

Radioactive Microspheres:

  • Y-90 is typically incorporated into microspheres, which are tiny particles used in radioembolization. These microspheres are designed to be injected into the hepatic artery (liver artery) and become lodged in the small blood vessels feeding the tumor.

 

Beta Radiation Emission:

  • Once the microspheres lodge in the tumor’s blood supply, Y-90 continuously emits beta radiation. This localized radiation damages and destroys the tumor cells, leading to tumor shrinkage and potentially cancer cell death.

 

Targeted Therapy:

  • The key advantage of using Y-90 is its targeted delivery, which minimizes radiation exposure to healthy tissue. The microspheres are designed to specifically target tumors, especially in the liver, thereby delivering a high dose of radiation directly to cancerous cells with reduced systemic toxicity.

Conditions Treated:

Liver Cancer:

  • Primary liver cancer (hepatocellular carcinoma) and liver metastases (secondary liver tumors) are the most common applications for Y-90 radioembolization. In these cases, selective internal radiation therapy (SIRT) is used to treat tumors that are difficult to reach with traditional treatments like surgery or external radiation.

 

Metastatic Tumors:

  • Y-90 radioembolization is particularly beneficial for patients with metastatic liver cancer. These are tumors that have spread from other organs, such as the colon, breast, or pancreas, to the liver. Yttrium-90 therapy helps deliver high doses of radiation directly to the metastatic cancer cells within the liver.

 

Other Solid Tumors:

  • While primarily used for liver cancer, Y-90 may also be explored in the treatment of other solid tumors where localized radiation can be delivered effectively.

Advantages of Yttrium-90:

Targeted Radiation Delivery:

  • The key benefit of Y-90 therapy is its precision. It can deliver a high dose of radiation directly to tumor cells in the liver while avoiding damage to surrounding healthy tissue, which is particularly important in organs with high radiation sensitivity.

 

Minimized Systemic Side Effects:

  • Since Y-90 is localized to the tumor site, it reduces the systemic side effects often associated with traditional chemotherapy and external radiation therapy, such as nausea, fatigue, and hair loss.

 

Effective for Inoperable Tumors:

  • Y-90 radioembolization is particularly useful for patients with inoperable liver tumors or those who are not candidates for surgery due to tumor size or location. It provides an option for patients who may not have other treatment options available.

 

Prolonged Treatment Effect:

  • The beta radiation from Y-90 can continue to affect the tumor cells over time, leading to sustained tumor control. This long-acting effect is beneficial for tumors that are difficult to shrink with a single dose.

 

Minimally Invasive:

  • The procedure is minimally invasive, requiring only the insertion of a catheter into the liver artery, which reduces the risk of complications and shortens recovery time compared to traditional surgery.

Yttrium-90 is a highly effective, targeted treatment for liver cancer and metastatic liver tumors. By delivering radiation directly to the tumor through radioactive microspheres, it minimizes systemic side effects and provides a precise, localized therapy option. While it offers numerous benefits, including reduced toxicity and effectiveness for inoperable tumors, its limitations include its primary use in liver cancer, risks associated with the procedure, and logistical challenges in treatment administration. Nonetheless, Y-90 remains a powerful tool in the arsenal of cancer treatments, particularly for liver tumors.